Loading patent…
OwnerJaun Jose Legarda Ibanezinventor
Estimating the term…
The present invention relates to the composition and methods of using a combination of a serotonin3 (5-HT3) receptor antagonist, such as ondansetron, and a selective chloride channel modulator, such as flumazenil, for treatment of patients with drug addiction or dependence. Examples of the drugs include prescription drugs as well as illegal drugs, such as, but not limited to, alcohol, cocaine, nicotine, marijuana, benzodiazepines and opiates. Furthermore, this combination can be used for treatment of patients suffering from central nervous system (CNS) disorders such as, but not limited to, depression, emotional and mood disorders and loss of memory.
A method for treating a patient with drug addiction or dependence or for treatment of a patient with a central nervous system (CNS) disorder, the method comprising administering to the patient a therapeutically effective amount of a combination comprising a serotonin3 (5-HT3) receptor antagonist and a selective chloride channel modulator.
A method for treating a patient with drug addiction or dependence or for treatment of a patient with a central nervous system (CNS) disorder, the method comprising administering a therapeutically effective amount of a combination of ondansetron and flumazenil in a single formulation to the patient.
A medicant composition for treatment of a condition selected from the group consisting of drug addiction, drug dependence, and a central nervous system disorder said composition comprising a therapeutically effective amount of a serotonin3 (5-HT3) receptor antagonist and a therapeutically effective amount of a selective chloride channel modulator.
Dependencies are inferred from the claim text.